期刊文献+

肝细胞肝癌中uPA及vimentin蛋白的表达及意义 被引量:4

Expression of uPA and vimentin in hepatocellular carcinoma and their significance
原文传递
导出
摘要 目的:探讨uPA及vimentin在肝细胞肝癌(HCC)组织中的表达及其临床病理意义。方法:应用免疫组化法检测HCC及其癌旁组织(88例)与正常肝组织(8例)中uPA及vimentin的表达情况,并分析两者与临床病理特征的关系及两者表达的相关性。结果:在HCC组织中uPA及vimentin蛋白阳性表达率分别为63.6%(56/88)和72.7%(64/88),两者均明显高于癌旁组织(27.3%和15.9%)和正常肝组织(12.5%和12.5%)(均P<0.0125);uPA和vimentin在HCC中的表达与门静脉癌栓及肝被膜浸润有关(P<0.05),且两者在HCC中的表达互呈正相关(r=0.227,P=0.034)。结论:在HCC中,uPA和vimentin的表达呈正相关,且两者的阳性表达与患者不良临床特征有关。 Objective: To investigate the expressions ofuPA and vimentin protein in hepatocellular carcinoma (HCC) and their clinicopathologic significance. Methods: The expressions of uPA and vimentin protein in HCC along with their paired adiacent tissues (88 cases) and normal liver tissues (8 cases) were determined by immumohistochemical staining. The relations of the expressions of the both proteins with the clinicopathologic characteristics of HCC patients, and the correlation between themselves were analyzed. Results: The positive expression rates of uPA and vimentin protein in HCC tissues were 63.6% and 72.7% respectively, and both were significantly higher than those in their ad)acent tissues (27.3% and 15.9%) and normal liver tissue (12.5% and 12.5%) (all P〈0.0125). The expressions ofuPA and vimentin protein in HCC were associated with the presence of portal vein tumor thrombus and liver capsule invasion (all P〈0.05), and there was a positive correlation between the expressions ofuPA and vimentin protein in HCC tissues (r=0.227, P=0.034). Conclusion: The expressions ofuPA and vimentin protein in HCC are positively correlated and both positive expressions are associated with the unfavorable clinical characteristics of the patients.
出处 《中国普通外科杂志》 CAS CSCD 北大核心 2013年第4期469-473,共5页 China Journal of General Surgery
基金 国家自然科学基金资助项目(30901452)
关键词 肝肿瘤 尿纤溶酶原激活物 VIMENTIN 免疫组织化学 Liver Neoplasms Urinary Plasminogen Activator Vimentin Immunohistochemistry
  • 相关文献

参考文献4

二级参考文献32

  • 1吴唯,吕新生,唐中华,张翼,李小荣,陈道瑾.乳腺癌组织中VEGF mRNA的表达及其临床意义[J].中国普通外科杂志,2004,13(11):813-816. 被引量:5
  • 2赵仲生,茹国庆,马杰.IGF-Ⅱ和HGF mRNA表达与胃癌微血管密度的关系[J].中华肿瘤杂志,2004,26(11):673-677. 被引量:27
  • 3唐金海,赵建华,徐甫保,秦建伟,龚建平.肿瘤切除和术后复发对乳腺癌患者血管生成平衡的影响[J].中国普通外科杂志,2005,14(9):672-675. 被引量:1
  • 4赵超尘,李君,王平,王学浩.酪丝亮肽治疗手术不能切除的原发性肝癌临床疗效观察[J].中国现代医学杂志,2007,17(3):357-359. 被引量:8
  • 5O'Brien K, Cokkinides V, Jemal A, et al. Cancer statistics for Hispanics, 2003. CA Cancer J Clin, 2003, 53(4):208-226.
  • 6Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008, 359(4):378-390.
  • 7Cheng A, Kang Y, Chen Z, et al. Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. J Clin Oncol, 2008, 26(20 Suppl):4509.
  • 8Hossain MM, Hosono-Fukao T, Tang R, et al. Direct detection of HSulf-1 and HSulf-2 activities on extracellular heparan sulfate and their inhibition by PI-88. Glycobiology, 2010, 20(2): 175-186.
  • 9Kudchadkar R, Gonzalez R, Lewis KD. PI-88: a novel inhibitor of angiogenesis. Expert Opin Investig Drugs, 2008, 17(11):1769-1776.
  • 10Liu CJ, Lee PH, Lin DY, et al. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage. J Hepatol, 2009, 50(5):958-968.

共引文献46

同被引文献73

  • 1de Bock CE, Wang Y. Clinical significance of uroki- nase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev 2004. 24:13-39 [PMID: 14595671 DOh 10.1002/med.10054].
  • 2Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001. 411:375-379 [PMID: 11357145 DOI: 10.1038/35077241].
  • 319uffy MJ. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 2004. 10:39-49 [PMID: 14754404 DOI: 10.2174/138161204 3453559].
  • 4Dutta S, Bandyopadhyay C, Bottero V, Veettil MV, Wilson L, Pins MR, Johnson KE, Warshall C, Chandran B. Angiogenin interacts with the plas- minogen activation system at the cell surface of breast cancer cells to regulate plasmin formation and cell migration. Mol Oncol 2014 Jan 4. [Epub ahead ofprintl [PMID: 24457100 DOI: 10.1016/ i.molonc.2013.12.017].
  • 5Montuori N, Cosimato V, Rinaldi L, Rea VE, Alfano D, Ragno P. uPAR regulates pericellular proteoly- sis through a mechanism involving integrins and fMLF-receptors. Thromb Haemost 2013. 109:309-318 [PMID: 23238745 DOh 10.1160/TH12-08-0546].
  • 6Poettler M, Unseld M, Mihaly-Bison J, Uhrin P, Koban F, Binder BR, Zielinski CC, Prager GW. The urokinase receptor (CD87) represents a central me- diator of growth factor-induced endothelial cell mi- gration. Thromb Haemost 2012. 108:357-366 [PMID: 22782499 DOI: 10.1160/THl1-12-0868].
  • 7Jirvinen HM, Laakkonen L, Haiko J, Johansson T, Juuti K, Suomalainen M, Buchrieser C, Kalkkinen N, Korhonen TK. Human single-chain urokinase is ac- tivated by the omptins PgtE of Salmonella enterica and Pla of Yersinia pestis despite mutations of ac- tive site residues. Mol Microbiol 2013. 89:507-517 [PMID: 23763588 DOh 10.1111/mrni.12293].
  • 8Beloglazova IB, Beabealasvilli RSh, Gursky YG, Bocharov EV, Mineev KS, Parfenova EV, Tkachuk VA. Structural investigations of recombinant uroki- nase growth factor-like domain. Biochemistry (Mosc) 2013. 78:517-530 [PMID: 23848154 DOI: 10.1134/ S0006297913050106].
  • 9Takada Y. Potential role of kringle-integrin interac-tion in plasmin and uPA actions (a hypothesis). J Biomed Biotechnol 2012. 2012:136302 [PMID: 23125522 DOI: 10.1155/2012/136302].
  • 10- I J Bager R, Kristensen TK, Jensen JK, Szczur A, Chris- tensen A, Andersen LM, Johansen JS, Larsen N, Baatrup E, Huang M, Ploug M, Andreasen PA. Uro- kinase-type plasminogen activator-like proteases in teleosts lack genuine receptor-binding epidermal growth factor-like domains. J Biol Chem 2012. 287: 27526-27536 [PMID: 22733817 DOI: 10.1074/jbc. Ml12.369207].

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部